Legal
A review of top officials at Memorial Sloan Kettering Cancer Center found that there were repeated violations on financial conflicts of interest. The review was conducted by law firm Debevoise & Plimpton and jointly reported by The New York Times and ProPublica.
Sino-American relations continue to show signs of strain after the administration of President Donald Trump ordered the Chinese majority owner of healthcare company PatientsLikeMe to sell his stake.
Amgen is suing Novartis, alleging a breach of the partnership and seeking to terminate the 2015 contract. Novartis, in response, filed a lawsuit accusing Amgen of inappropriately attempting to end the alliance.
The U.S. Federal Trade Commission (FTC) won a suit against India-based scientific publisher, Omics International, alleging that the publisher operated hundreds of fake scientific journals with deceptive business practices.
The lawsuit alleges that Soon-Shiong acquired the promising cancer treatment in order to prevent it from coming to market and challenging revenues from Celgene’s Abraxane, a drug Soon-Shiong developed.
It’s not a secret to say that tax incentives play a significant role in a municipality’s ability to attract new businesses. In Massachusetts, a state with a heavy biotech presence, tax incentives have been able to help small towns compete with large biotech and pharma hubs, like Cambridge.
Embattled Purdue Pharma has agreed to pay $270 million to settle a lawsuit brought against the company over the marketing of its opioid painkiller OxyContin, according to reports.
Numerous top biopharma executives met recently in Manalapan, Florida for the R&D Leadership Summit. Although a wide range of topics were discussed, certain areas rose to the top as being of particular concern to industry leadership. Here’s a look at a few of those concerns.
Falsified Data Forces Duke to Pay $112 Million Settlement, Other Universities Under Scrutiny as Well
Duke University has agreed to pay the U.S. government more than $112 million to settle allegations that a university-associated researcher falsified claims in order to obtain funding from the National Institutes of Health and other federal agencies.
Both Bayer and J&J claim the lawsuits are without merit but believe that the $775 million settlement will allow the companies to move on from costly litigation.
PRESS RELEASES